Skip to main content
. 2018 Jul 24;9(57):31077–31089. doi: 10.18632/oncotarget.25780

Figure 4. Ruxolitinib suppresses viable cell number of EBV-infected T or NK cells.

Figure 4

(A) EBV-infected T- or NK-cell lines were treated with ruxolitinib, as indicated, for 48 h, and the number of viable cells was estimated by an XTT assay and expressed in arbitrary units. The data are shown as mean±standard deviations (SD) of three independent experiments. (B) the PBMCs from 3 patients with CAEBV and 1 healthy donor were treated with ruxolitinib, as indicated, in the presence of IL-2 for 72 h, and the viable cell number was estimated by an XTT assay and expressed in arbitrary units. The data are presented as mean±SD of three independent experiments. (C) EBV-infected T- or NK-cell lines were treated with ruxolitinib for 48 h, as indicated, and then analyzed. Cells were stained with Annexin V and PI and subsequently analyzed by flow cytometry.